Table 4.
Variable | Levels | Non-ASD | ASD | OR | 95% CI | p value |
---|---|---|---|---|---|---|
Cumulative dose of sOT | 0 mU | 57 | 51 | 1 | ||
1st level | 37 | 20 | 0.61 | 0.26–1.41 | 0.250 | |
2nd level | 25 | 25 | 1.62 | 0.63–4.16 | 0.310 | |
3rd level | 18 | 41 | 2.79 | 1.10–7.06 | 0.031 | |
Maximum dose rate | 0 mU/min | 57 | 51 | 1 | ||
1st level | 29 | 23 | 0.85 | 0.37–1.97 | 0.709 | |
2nd level | 31 | 26 | 1.27 | 0.55–2.95 | 0.575 | |
3rd level | 20 | 37 | 1.97 | 0.83–4.69 | 0.127 | |
Time of exposure | 0 min | 57 | 51 | 1 | ||
1st level | 39 | 17 | 0.52 | 0.22–1.22 | 0.134 | |
2nd level | 23 | 28 | 1.79 | 0.69–4.61 | 0.229 | |
3rd level | 18 | 41 | 3.48 | 1.29–9.41 | 0.014 |
All variables are categorical and coded so that OR > 1 indicates higher odds of ASD. Variables controlled for were maternal hypertension, maternal diabetes, maternal education, indication for delivery (including fetal indications), birth weight, maternal body mass index, mode of delivery, child race, smoking during pregnancy, alcohol use during pregnancy, and paternal age. The exposure variables (cumulative dose of sOT, maximum dose rate, and time of exposure) were run in separate models. Each model consisted of the exposure variable, covariates, and the outcome. ASD: autism spectrum disorder; OR: odds ratio, CI: confidence interval; sOT: synthetic oxytocin.